Skip to content

Treatment Of Fever In The Emergency Department

Treatment Of Fever And Associated Symptoms In The Emergency Department: Which Drug To Choose?

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05814302
Enrollment
324
Registered
2023-04-14
Start date
2021-06-01
Completion date
2022-07-01
Last updated
2023-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fever

Keywords

Fever, Paracetamol, Paracetamol/Ibuprofen, Emergency Department

Brief summary

Fever is a frequent cause of admission to the Emergency Department (ED) around the world. While it can be caused by a wide range of conditions, the most effective treatment based on its etiology is still undetermined. This observational, prospective, single-center study enrolled adult patients who accessed the ED for fever, with the aim to define the most effective treatment for them.

Detailed description

Physicians were free to administer paracetamol 1000 mg (P), the combination paracetamol 500 mg/ibuprofen 150 mg (PI) or Ibuprofen 600 mg (I).The primary endpoint was both 1-degree and 1-point reduction in body temperature for all associated symptoms on the Numeric Rating Scale (NRS) after 1 hour (T1). Secondary endpoint was the reduction of at least 2 points on the NRS after two hours (T2). Adverse events, the needing of a rescue therapy and the response based on the underlying etiology (bacterial, viral, or immune/neoplastic) were also evaluated.

Interventions

DRUGParacetamol

Emergency physicians were free to administer paracetamol 1000 mg (P), the combination paracetamol 500 mg/ibuprofen 150 mg (PI) or Ibuprofen 600 mg (I)

Sponsors

Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 95 Years
Healthy volunteers
No

Inclusion criteria

* fever with/without associated symptoms * adults who had given their consent to participate in the study.

Exclusion criteria

* age \< 18 years old * contraindications or allergies to Paracetamol, Ibuprofen or to the combination Paracetamol/Ibuprofen * patients unable to take oral drugs * patients who did not express their consent to participate to the study

Design outcomes

Primary

MeasureTime frameDescription
body temperature1 hourthe reduction of 1-degree of body temperature after 1 hour (T1) after the drug administration
Numerical Rating Scale (NRS)1 hourthe reduction of 1-point for all associated symptoms on NRS after 1 hour (T1) after the drug administration. NRS is a 0-10 scale tool to assess pain severity, with zero that means no pain and 10 the worst pain.

Secondary

MeasureTime frameDescription
the reduction of at least 2 points on the Numerical Rating Scale (NRS) after two hours (T2) after the drug administration2 hoursthe secondary endpoint was to evaluate the number of patients (%) who obtained a reduction of at least 2 points on the NRS scale, in at least one of the symptoms associated with fever 2 hours after the antypiretic administration (T2). NRS is a 0-10 scale tool to assess pain severity, with zero that means no pain and 10 the worst pain.
rescue therapy2 hoursto identify the number of patients (%) who needed a rescue therapy
adverse events2 hoursto identify the percentage (%) of adverse events

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026